Osteoclast differentiation and activation

[1]  W. Vainchenker,et al.  Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. , 2003, Blood.

[2]  D. Lacey,et al.  Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.

[3]  Steven W. Martin,et al.  A Phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases , 2003, Cancer.

[4]  Noriaki Yoshida,et al.  U0126 and PD98059, Specific Inhibitors of MEK, Accelerate Differentiation of RAW264.7 Cells into Osteoclast-like Cells* , 2002, The Journal of Biological Chemistry.

[5]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[6]  W. Dougall,et al.  A RANK/TRAF6-dependent Signal Transduction Pathway Is Essential for Osteoclast Cytoskeletal Organization and Resorptive Function* , 2002, The Journal of Biological Chemistry.

[7]  E. Wagner,et al.  JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms , 2002, Journal of Cell Science.

[8]  L. Hofbauer,et al.  Osteoprotegerin deficiency and juvenile Paget's disease. , 2002, The New England journal of medicine.

[9]  B. Riggs,et al.  The Immunosuppressant Rapamycin, Alone or with Transforming Growth Factor-b, Enhances Osteoclast Differentiation of RAW264.7 Monocyte-Macrophage Cells in the Presence of RANK-Ligand , 2002, Calcified Tissue International.

[10]  T. Takeya,et al.  Large Scale Gene Expression Analysis of Osteoclastogenesisin Vitro and Elucidation of NFAT2 as a Key Regulator* , 2002, The Journal of Biological Chemistry.

[11]  S. Marks,et al.  The osteopetrotic mutation toothless (tl) is a loss-of-function frameshift mutation in the rat Csf1 gene: Evidence of a crucial role for CSF-1 in osteoclastogenesis and endochondral ossification , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. Yasuda,et al.  Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis , 2002, Journal of Bone and Mineral Metabolism.

[13]  I. Reid,et al.  A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. , 2002, Human molecular genetics.

[14]  T. Mak,et al.  Immunology: A block at the toll gate , 2002, Nature.

[15]  M. Kumegawa,et al.  Regulation of Receptor Activator of NF-κB Ligand-induced Osteoclastogenesis by Endogenous Interferon-β (INF-β) and Suppressors of Cytokine Signaling (SOCS) , 2002, The Journal of Biological Chemistry.

[16]  T. Nishihara,et al.  p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. , 2002, Endocrinology.

[17]  Hong-Hee Kim,et al.  TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. , 2002, Journal of biochemistry and molecular biology.

[18]  Hao Wu,et al.  Distinct molecular mechanism for initiating TRAF6 signalling , 2002, Nature.

[19]  Ulrich Siebenlist,et al.  NF‐κB p50 and p52 Expression Is Not Required for RANK‐Expressing Osteoclast Progenitor Formation but Is Essential for RANK‐ and Cytokine‐Mediated Osteoclastogenesis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  E. Eriksen,et al.  Polymorphisms in the Osteoprotegerin Gene Are Associated With Osteoporotic Fractures , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  Sandrine Bongiovanni,et al.  Transcriptional Program of Mouse Osteoclast Differentiation Governed by the Macrophage Colony-stimulating Factor and the Ligand for the Receptor Activator of NFκB* , 2002, The Journal of Biological Chemistry.

[22]  J. Baek,et al.  Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression , 2002, Experimental & Molecular Medicine.

[23]  P. Stashenko,et al.  c‐myc Is Required for Osteoclast Differentiation , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  Kozo Nakamura,et al.  RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β , 2002, Nature.

[25]  Y. Kadono,et al.  Possible Involvement of IκB Kinase 2 and MKK7 in Osteoclastogenesis Induced by Receptor Activator of Nuclear Factor κB Ligand , 2002 .

[26]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[27]  K. Preissner,et al.  RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[28]  Michael C. Ostrowski,et al.  Microphthalmia Transcription Factor Is a Target of the p38 MAPK Pathway in Response to Receptor Activator of NF-κB Ligand Signaling* , 2002, The Journal of Biological Chemistry.

[29]  C. Murphy,et al.  TNFα Potently Activates Osteoclasts, through a Direct Action Independent of and Strongly Synergistic with RANKL. , 2002, Endocrinology.

[30]  Shi Wei,et al.  Interleukin-4 Reversibly Inhibits Osteoclastogenesis via Inhibition of NF-κB and Mitogen-activated Protein Kinase Signaling* , 2002, The Journal of Biological Chemistry.

[31]  N. Sakurai,et al.  Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. , 2002, Molecular and cellular biology.

[32]  M. Whyte,et al.  Expansile Skeletal Hyperphosphatasia Is Caused by a 15‐Base Pair Tandem Duplication in TNFRSF11A Encoding RANK and Is Allelic to Familial Expansile Osteolysis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  M. Kumegawa,et al.  Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta ) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation. , 2002, The Journal of biological chemistry.

[34]  J. Penninger,et al.  RANK-L and RANK: T cells, bone loss, and mammalian evolution. , 2002, Annual review of immunology.

[35]  Matthew J. Silva,et al.  SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts , 2002, Nature Network Boston.

[36]  S. Khosla,et al.  Minireview: the OPG/RANKL/RANK system. , 2001, Endocrinology.

[37]  B. Olsen,et al.  Mouse models of abnormal skeletal development and homeostasis. , 2001, Trends in genetics : TIG.

[38]  E. Wagner,et al.  Genetic control of skeletal development. , 2001, Current opinion in genetics & development.

[39]  Y. Kadono,et al.  Segregation of TRAF6‐mediated signaling pathways clarifies its role in osteoclastogenesis , 2001, The EMBO journal.

[40]  A. Nakanishi,et al.  The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  B. Riggs,et al.  Regulation of osteoclastogenesis and RANK expression by TGF‐β1 , 2001 .

[42]  R. L. Cain,et al.  Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. , 2001, Endocrinology.

[43]  Hiroshi Takayanagi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ , 2000, Nature.

[44]  M. Tsujimoto,et al.  Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)* , 2000, The Journal of Biological Chemistry.

[45]  T. Martin,et al.  Therapeutic approaches to bone diseases. , 2000, Science.

[46]  T. Chambers.  Regulation of the differentiation and function of osteoclasts , 2000, The Journal of pathology.

[47]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[48]  T. Martin,et al.  Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. , 2000, Endocrinology.

[49]  D L Lacey,et al.  Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. , 2000, The American journal of pathology.

[50]  D L Lacey,et al.  RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Sundeep Khosla,et al.  The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[52]  R. Wallace,et al.  Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis , 2000, Nature Genetics.

[53]  T. Miyata,et al.  Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of C-Fms and Receptor Activator of Nuclear Factor κb (Rank) Receptors , 1999, The Journal of experimental medicine.

[54]  H. Hanafusa,et al.  TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. , 1999, Molecular cell.

[55]  Yuqiong Liang,et al.  Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification , 1999, Nature Genetics.

[56]  W. Dougall,et al.  RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.

[57]  S. Morony,et al.  A Chimeric Form of Osteoprotegerin Inhibits Hypercalcemia and Bone Resorption Induced by IL‐1β, TNF‐α, PTH, PTHrP, and 1,25(OH)2D3 , 1999 .

[58]  E. Jimi,et al.  Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. , 1999, Journal of immunology.

[59]  D. Lacey,et al.  The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.

[60]  S. Morony,et al.  TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.

[61]  S. Morony,et al.  Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[62]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[63]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[64]  H. Yasuda,et al.  RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.

[65]  W. Dougall,et al.  The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR)-associated Factors in the Signaling Mechanisms of Receptor Activator of NF-κB, a Member of the TNFR Superfamily* , 1998, The Journal of Biological Chemistry.

[66]  G. Rodan.  Bone homeostasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[67]  B. Aggarwal,et al.  Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. , 1998, The Journal of biological chemistry.

[68]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[69]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[70]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[71]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[72]  Ulrich Siebenlist,et al.  Requirement for NF-κB in osteoclast and B-cell development , 1997 .

[73]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[74]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[75]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[76]  E. Wagner,et al.  c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. , 1994, Science.

[77]  S. Marks,et al.  Osteoclast biology: lessons from mammalian mutations. , 1989, American journal of medical genetics.

[78]  Sheila J. Jones,et al.  Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. , 1988, Endocrinology.